690 related articles for article (PubMed ID: 26525846)
1. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
Katz JN; Smith SR; Collins JE; Solomon DH; Jordan JM; Hunter DJ; Suter LG; Yelin E; Paltiel AD; Losina E
Osteoarthritis Cartilage; 2016 Mar; 24(3):409-18. PubMed ID: 26525846
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis.
Smith SR; Katz JN; Collins JE; Solomon DH; Jordan JM; Suter LG; Yelin EH; David Paltiel A; Losina E
Arthritis Care Res (Hoboken); 2017 Feb; 69(2):234-242. PubMed ID: 27111538
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation.
Losina E; Usiskin IM; Smith SR; Sullivan JK; Smith KC; Hunter DJ; Messier SP; Paltiel AD; Katz JN
Osteoarthritis Cartilage; 2018 May; 26(5):641-650. PubMed ID: 29481917
[TBL] [Abstract][Full Text] [Related]
5. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.
Losina E; Michl G; Collins JE; Hunter DJ; Jordan JM; Yelin E; Paltiel AD; Katz JN
Osteoarthritis Cartilage; 2016 May; 24(5):776-85. PubMed ID: 26746146
[TBL] [Abstract][Full Text] [Related]
6. Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.
Capel M; Tornero J; Zamorano JL; Oyagüez I; Casado MÁ; Sánchez-Covisa J; Lanas A
Reumatol Clin; 2014; 10(4):210-7. PubMed ID: 24380809
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.
Yen ZS; Lai MS; Wang CT; Chen LS; Chen SC; Chen WJ; Hou SM
J Rheumatol; 2004 Sep; 31(9):1797-803. PubMed ID: 15338503
[TBL] [Abstract][Full Text] [Related]
8. An economic model of long-term use of celecoxib in patients with osteoarthritis.
Loyd M; Rublee D; Jacobs P
BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
[TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Brereton N; Pennington B; Ekelund M; Akehurst R
J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
[TBL] [Abstract][Full Text] [Related]
11. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
Inotai A; Mészáros A
Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective.
Wielage RC; Patel AJ; Bansal M; Lee S; Klein RW; Happich M
Arthritis Care Res (Hoboken); 2014 May; 66(5):702-8. PubMed ID: 24877251
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis.
Kamath CC; Kremers HM; Vanness DJ; O'Fallon WM; Cabanela RL; Gabriel SE
Value Health; 2003; 6(2):144-57. PubMed ID: 12641865
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of duloxetine for knee OA subjects: the role of pain severity.
Sullivan JK; Huizinga J; Edwards RR; Hunter DJ; Neogi T; Yelin E; Katz JN; Losina E
Osteoarthritis Cartilage; 2021 Jan; 29(1):28-38. PubMed ID: 33171315
[TBL] [Abstract][Full Text] [Related]
19. [Economic evaluation of tramadol/paracetamol in the management of pain in patients with osteoarthritis in Spain].
Vidal J; Benito P; Manresa A; Ly-Pen D; Batlle E; Blanco FJ; Brosa M; Nieves D
Reumatol Clin; 2011; 7(4):241-7. PubMed ID: 21794825
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee.
Schiff M; Minic M
J Rheumatol; 2004 Jul; 31(7):1373-83. PubMed ID: 15229960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
